within Pharmacolibrary.Drugs.ATC.R;

model R01BA51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.00035,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0028,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005833333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01BA51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Phenylpropanolamine is a sympathomimetic amine used as a decongestant and appetite suppressant. It was formerly used in various over-the-counter cold and flu remedies, often in combination with other agents such as antihistamines and analgesics. Due to concerns about increased risk of hemorrhagic stroke, it has been withdrawn from the market or its use greatly restricted in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration of phenylpropanolamine containing combinations.</p><h4>References</h4><ol><li><p>Hendeles, L (1993). Selecting a decongestant. <i>Pharmacotherapy</i> 13(6 Pt 2) 129S–146S. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7507590/\">https://pubmed.ncbi.nlm.nih.gov/7507590</a></p></li><li><p>Schran, HF, et al., &amp; Gelbert, MB (1996). The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. <i>Journal of clinical pharmacology</i> 36(10) 911–922. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1996.tb04758.x\">10.1002/j.1552-4604.1996.tb04758.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8930778/\">https://pubmed.ncbi.nlm.nih.gov/8930778</a></p></li><li><p>Gacci, M, et al., &amp; Serni, S (2015). Tolterodine in the Treatment of Male LUTS. <i>Current urology reports</i> 16(9) 60–None. DOI:<a href=\"https://doi.org/10.1007/s11934-015-0531-9\">10.1007/s11934-015-0531-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26149965/\">https://pubmed.ncbi.nlm.nih.gov/26149965</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01BA51;
